Restoration of tumor suppressor function by induction of translational read thro...
Restoration of tumor suppressor function by induction of translational read through of premature termination codons a strategy for improved cancer therapy
Tumor suppressor genes such as TP53, RB1, PTEN and APC are frequently inactivated in sporadic and inherited human tumors. A significant fraction of the mutations in these genes are nonsense mutations that lead to premature termina...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
P53LAZARUS
Tumour suppressor p53 structure stability and novel anti c...
1M€
Cerrado
TMP53COMPMIX
Transcriptional mutagenesis in mammalian cell systems p53 s...
100K€
Cerrado
RTI2018-099017-A-I00
IDENTIFICACION DE LOS MECANISMOS DE REPARACION DE ADN CRITIC...
133K€
Cerrado
Oncoswitch
In vivo analysis of the p53 and p73 tumor suppressors using...
209K€
Cerrado
SAF2015-71381-R
ANALISIS DE LA INTERACCION YIN-YANG ENTRE TP53 Y TP73 EN LA...
206K€
Cerrado
Información proyecto TRANSREAD
Duración del proyecto: 65 meses
Fecha Inicio: 2016-08-30
Fecha Fin: 2022-02-28
Líder del proyecto
KAROLINSKA INSTITUTET
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
2M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Tumor suppressor genes such as TP53, RB1, PTEN and APC are frequently inactivated in sporadic and inherited human tumors. A significant fraction of the mutations in these genes are nonsense mutations that lead to premature termination of translation and expression of truncated unstable and non-functional proteins. We will identify and characterize novel molecules that can induce translational read-through of premature termination codons in nonsense mutant TP53 and expression of full length p53 protein. Hits will be tested for their effect on nonsense mutant RB1, PTEN and APC. We will also elucidate the molecular mechanism of action of the identified compounds by CETSA and other techniques. Moreover, we will test hit compounds on primary tumor cells from patients ex vivo, and generate mouse knock-in tumor models with nonsense mutant tumor suppressor genes for further characterization of hits. We will take the most promising hits through preclinical development towards clinical trials. Our aim is to develop novel and efficient targeted therapy for tumors with nonsense mutations in the TP53, RB1, PTEN and/or APC tumor suppressor genes.